U.S. markets open in 3 hours 45 minutes
  • S&P Futures

    3,882.25
    -16.50 (-0.42%)
     
  • Dow Futures

    31,422.00
    -87.00 (-0.28%)
     
  • Nasdaq Futures

    13,216.25
    -63.50 (-0.48%)
     
  • Russell 2000 Futures

    2,255.40
    -19.40 (-0.85%)
     
  • Crude Oil

    60.67
    +0.03 (+0.05%)
     
  • Gold

    1,726.10
    +3.10 (+0.18%)
     
  • Silver

    26.31
    -0.37 (-1.40%)
     
  • EUR/USD

    1.2026
    -0.0033 (-0.28%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.55
    -4.40 (-15.74%)
     
  • GBP/USD

    1.3891
    -0.0030 (-0.21%)
     
  • USD/JPY

    106.8770
    +0.1470 (+0.14%)
     
  • BTC-USD

    49,164.76
    +1,843.08 (+3.89%)
     
  • CMC Crypto 200

    988.89
    +2.24 (+0.23%)
     
  • FTSE 100

    6,620.83
    +32.30 (+0.49%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Recap: Sage Therapeutics Q2 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Sage Therapeutics (NASDAQ:SAGE) were flat in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 36.59% over the past year to ($2.08), which beat the estimate of ($2.66).

Revenue of $1,089,000 rose by 24.74% from the same period last year, which beat the estimate of $890,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 10, 2020

View more earnings on SAGE

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/kkevgsu3

Recent Stock Performance

52-week high: $174.73

Company's 52-week low was at $25.01

Price action over last quarter: Up 30.05%

Company Description

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.